PDF(327 KB)

Chinese Journal of Blood Purification ›› 2005, Vol. 4 ›› Issue (8) : 437-439.

论著

Author information +

History +

Abstract

Objective Microinflammation is common in hemodialysis patients. The purpose of our study is to investigate the effects of simvastatin on the levels of C-reactive protein (CRP) and D-dimer in hemodialysis patients. Methods In a single-blind randomized trial,We evaluated 51 HD patients with total plasma cholesterol over 6.0mmol/L and administered simvastatin 20mg/d for 12 weeks. Cholesterol, triglyceride, LDL-cholesterol, high-density lipoprotein (HDL), lipoprotein(a) and the inflammatory marker CRP, and D-dimer (a marker of intravascular coagulation) were measured at baseline and again at 12 weeks. Results In the treatment group (n=30), simvastatin administration for 12 weeks significantly reduced total cholesterol, triglyceride, LDL-cholesterol, and increased HDL. The levels of CRP decreased obviously from (10±1.3)mg/L at baseline to (4.8±0.9)mg/L at 12 weeks (P＜0.001) and D-dimer from (1.03±0.8)μg/ml at baseline to (0.8±0.2)μg/ml after 12 weeks treatment. Whereas simvastatin increased serum albumin levels from (30±10)g/L to (34±11)g/L (P＜0.05). The negative relationship between serum albumin levels and serum CRP levels was significant (r=-0.85, P＜0.01). Conclusions These results show that simvastatin exhibits comparable favourable effects on lipid profiles in patients with HD. Moreover, the reduction of serum CRP and D-dimer levels as shown in our investigation may indicate that simvastatin exhibits favourable effects on microinflammation and coagulation in HD patients.